Table 1 Differentially expressed microRNAs in all studies along with fold changes and study characteristics
From: A systematic review, meta-analysis, and network analysis of diagnostic microRNAs in glaucoma
| Â | Author, year | Country | Sample | Sample size | Detection method | Glaucoma patients | Controls | Differentially expressed miRNA | Fold change/relative expression | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NO | Type | Mean age (± SD) | F/M | NO | Type | Mean age (± SD) | F/M | ||||||||
1 | Hindle et al.,2019 | United States | Plasma | 28 | RT-PCR | 17 | POAG | 74.67 (± 6.04) | 17/0 | 11 | Cataract, anatomical narrow angle | 73 (± 4.74) | 11/0 | 637 | 2.53 Up-regulated |
2 | Hindle et al.,2019 | United States | Plasma | 28 | RT-PCR | 17 | POAG | 74.67 (± 6.04) | 17/0 | 11 | Cataract, anatomical narrow angle | 73 (± 4.74) | 11/0 | 1306-5p | 1.34 Up-regulated |
3 | Hindle et al.,2019 | United States | Plasma | 28 | RT-PCR | 17 | POAG | 74.67 (± 6.04) | 17/0 | 11 | Cataract, anatomical narrow angle | 73 (± 4.74) | 11/0 | 3159 | 2.31 Up-regulated |
4 | Hubens et al.,2021 | The Netherlands | Aqueous humor | 19 | Next-generation sequencing | 9 | POAG | 75.33 (± 4.98) | 5/4 | 10 | Cataract | 75.8 (± 10.62) | 3/7 | 30a-3p | Up-regulated |
5 | Hubens et al.,2021 | The Netherlands | Aqueous humor | 19 | Next-generation sequencing | 9 | POAG | 75.33 (± 4.98) | 5/4 | 10 | Cataract | 75.8 (± 10.62) | 3/7 | 143-3p | Up-regulated |
6 | Hubens et al.,2021 | The Netherlands | Aqueous humor | 19 | Next-generation sequencing | 9 | POAG | 75.33 (± 4.98) | 5/4 | 10 | Cataract | 75.8 (± 10.62) | 3/7 | 221-3p | Up-regulated |
7 | Hubens et al.,2021 | The Netherlands | Aqueous humor | 19 | Next-generation sequencing | 9 | POAG | 75.33 (± 4.98) | 5/4 | 10 | Cataract | 75.8 (± 10.62) | 3/7 | 211-5p | Up-regulated |
8 | Hubens et al.,2021 | The Netherlands | Aqueous humor | 19 | Next-generation sequencing | 9 | POAG | 75.33 (± 4.98) | 5/4 | 10 | Cataract | 75.8 (± 10.62) | 3/7 | 486-5p | Down-regulated |
9 | Hubens et al.,2021 | The Netherlands | Aqueous humor | 19 | Next-generation sequencing | 9 | POAG | 75.33 (± 4.98) | 5/4 | 10 | Cataract | 75.8 (± 10.62) | 3/7 | 451a | Down-regulated |
10 | Hubens et al.,2021 | The Netherlands | Aqueous humor | 19 | Next-generation sequencing | 9 | POAG | 75.33 (± 4.98) | 5/4 | 10 | cataract | 75.8 (± 10.62) | 3/7 | 92a-3p | Down-regulated |
11 | Liu et al.,2019 | China | Serum | 52 | qRT-PCR | 26 | POAG | 39.8 (± 12.1) | 6/20 | 26 | Healthy | 39.6 (± 13.7) | 8/18 | 210-3p (screening) | 1.05 ± 0.08 fold in control 2.52 ± 0.55 fold in POAG Up-regulated |
12 | Liu et al.,2019 | China | Serum | 66 | qRT-PCR | 33 | POAG | 41.2 (± 12.7) | 8/25 | 33 | Healthy | 42.8 (± 11.1) | 7/26 | 210-3p (validation) | 1.22 ± 0.15 fold in control 2.54 ± 0.39 fold in POAG Up-regulated |
13 | Liu et al.,2019 | China | Serum | 52 | qRT-PCR | 26 | POAG | 39.8 (± 12.1) | 6/20 | 26 | Healthy | 39.6 (± 13.7) | 8/18 | 885-5p (screening) | 1.22 ± 0.18 fold in control 1.44 ± 0.32 fold in POAG Up-regulated |
14 | Raga-Cervera et al.,2021 | Spain | Tears | 42 | Next-generation sequencing | 20 | POAG | 64.5 (± 1.4) | 52.4/47.6 | 22 | Ocular hypertension without neurodegeneration signs (OHT) | 61.1 (± 2.4) | 66.7/33.3 | 26b-5p | 0.855 Up-regulated |
15 | Raga-Cervera et al.,2021 | Spain | Tears | 42 | Next-generation sequencing | 20 | POAG | 64.5 (± 1.4) | 52.4/47.6 | 22 | Ocular hypertension without neurodegeneration signs (OHT) | 61.1 (± 2.4) | 66.7/33.3 | 27a-3p | 0.774 Up-regulated |
16 | Raga-Cervera et al.,2021 | Spain | Tears | 42 | Next-generation sequencing | 20 | POAG | 64.5 (± 1.4) | 52.4/47.6 | 22 | Ocular hypertension without neurodegeneration signs (OHT) | 61.1 (± 2.4) | 66.7/33.3 | 152-3p | 0.753 Up-regulated |
17 | Raga-Cervera et al.,2021 | Spain | Tears | 42 | Next-generation sequencing | 20 | POAG | 64.5 (± 1.4) | 52.4/47.6 | 22 | Ocular hypertension without neurodegeneration signs (OHT) | 61.1 (± 2.4) | 66.7/33.3 | 30e-5p | 0.901 Up-regulated |
18 | Raga-Cervera et al.,2021 | Spain | Tears | 42 | Next-generation sequencing | 20 | POAG | 64.5 (± 1.4) | 52.4/47.6 | 22 | Ocular hypertension without neurodegeneration signs (OHT) | 61.1 (± 2.4) | 66.7/33.3 | 125b-2-5p | 0.529 Up-regulated |
19 | Raga-Cervera et al.,2021 | Spain | Tears | 42 | Next-generation sequencing | 20 | POAG | 64.5 (± 1.4) | 52.4/47.6 | 22 | Ocular hypertension without neurodegeneration signs (OHT) | 61.1 (± 2.4) | 66.7/33.3 | 224-5p | 0.745 Up-regulated |
20 | Raga-Cervera et al.,2021 | Spain | Tears | 42 | Next-generation sequencing | 20 | POAG | 64.5 (± 1.4) | 52.4/47.6 | 22 | Ocular hypertension without neurodegeneration signs (OHT) | 61.1 (± 2.4) | 66.7/33.3 | 151a-3p |  − 0.417 Down-regulated |
21 | Raga-Cervera et al.,2021 | Spain | Tears | 42 | Next-generation sequencing | 20 | POAG | 64.5 (± 1.4) | 52.4/47.6 | 22 | Ocular hypertension without neurodegeneration signs (OHT) | 61.1 (± 2.4) | 66.7/33.3 | 1307-3p |  − 1 Down-regulated |
22 | Tamkovich et al.,2019 | Russia | Tears | 62 | RT-PCR | 33 | POAG | 52–81 Y/O median 65 | 22/11 | 29 | Healthy persons | 44–79 Y/O Median 63 |  | 146-b | 32.70 ± 0.67 in HPs 34.03 ± 1.17 in POAG Up-regulated |
23 | Tamkovich et al.,2019 | Russia | Tears | 62 | RT-PCR | 33 | POAG | 52–81 Y/O median 65 | 22/11 | 29 | Healthy persons | 44–79 Y/O Median 63 |  | 126 | 33.71 ± 0.54 in HPs 34.48 ± 0.70 in POAG Up-regulated |
24 | Tamkovich et al.,2019 | Russia | Tears | 62 | RT-PCR | 33 | POAG | 52–81 Y/O median 65 | 22/11 | 29 | Healthy persons | 44–79 Y/O Median 63 |  | 16 | 36.15 ± 0.88 in HPs 38.36 ± 1.24 in POAG Up-regulated |
25 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 4507 | 0.728 Down-regulated |
26 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 3620-5p | 0.622 Down-regulated |
27 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 4484 | 1.639 Up-regulated |
28 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 5001-5p | 0.718 Down-regulated |
29 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 6132 | 0.71 Down-regulated |
30 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 6515-3p | 1.413 Up-regulated |
31 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 4467 | 0.79 Down-regulated |
32 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 3663-3p | 1.432 Up-regulated |
33 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 187-5p | 0.524 Down-regulated |
34 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 4433-3p | 1.474 Up-regulated |
35 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 6717-5p | 1.909 Up-regulated |
36 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 6722-3p | 0.517 Down-regulated |
37 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 4725-3p | 1.588 Up-regulated |
38 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 1202 | 1.388 Up-regulated |
39 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 3197 | 1.454 Up-regulated |
40 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 4749-5p | 0.794 Down-regulated |
41 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 1260b | 0.659 Down-regulated |
42 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 4634 | 0.738 Down-regulated |
43 | Tanaka et al.,2014 | Japan |  | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 4259 | 1.981 Down-regulated |
44 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 92a-2-5p | 2.331 Up-regulated |
45 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 4449 | 1.926 Up-regulated |
46 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 1587 | 0.483 Down-regulated |
47 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 486-3p | 0.436 Down-regulated |
48 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 3185 | 0.642 Down-regulated |
49 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 940 | 0.303 Down-regulated |
50 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 3652 | 0.335 Down-regulated |
51 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 3135b | 0.626 Down-regulated |
52 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 5572 | 0.437 Down-regulated |
53 | Tanaka et al.,2014 | Japan | Aqueous humor | 20 | Microarray system | 10 | 4 cataract and POAG 4 POAG 2 PEX | 72.8 (± 3) | 4/6 | 10 | 5 cataract and 5 epiretinal membrane | 71.1 (± 2.6) | 7/3 | 4640-5p | 0.525 Down-regulated |